Curated Biopharma Press Releases
AI-curated to help biopharma service providers uncover new opportunities faster.
Showing 1-19 of 234 press releases for the past 10 days. to see more.
Phase 1 clinical trials
Nov 19, 2025
9:00 AM EST
Tinostamustine Shows Early Signals of Activity in Phase 1 Glioblastoma Trial
Stamford, Connecticut, United States
NeurologyOncology
Phase 2 clinical trials
Nov 19, 2025
9:00 AM EST
Funding and investments
Nov 19, 2025
8:36 AM EST
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Houston, Texas, United States
DermatologyNeurologyOncologyRare Diseases
Phase 1 clinical trials
Nov 19, 2025
8:05 AM EST
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
Plymouth Meeting, Pennsylvania, United States
Neurology
Funding and investments
Nov 19, 2025
7:00 AM EST
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
San Francisco, California, United States
Oncology
Phase 2 clinical trials
Nov 19, 2025
7:00 AM EST
Funding and investments
Nov 19, 2025
12:01 AM EST
Rafa Laboratories Awarded up to $186 Million by BARDA to Develop a Life-Saving Intramuscular TXA Injection for Prehospital Care
Jerusalem, None, Israel
Hematology
Phase 2 clinical trials
Nov 18, 2025
4:15 PM EST
Funding and investments
Nov 18, 2025
12:00 PM EST
Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Burlington, Massachusetts, United States
Immunology
Phase 1 clinical trials
Nov 18, 2025
8:30 AM EST
Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer
SYDNEY, New South Wales, Australia
OncologyUrology
Regulatory submissions
Nov 18, 2025
8:00 AM EST
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
Malvern, Pennsylvania, United States
Neurology
Phase 1 clinical trials
Nov 18, 2025
7:25 AM EST
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
Miramar, Florida, United States
DermatologyImmunology
Phase 1 clinical trials
Nov 18, 2025
7:00 AM EST
Vast Therapeutics Completes First Milestone in Phase 1 Clinical Program
Morrisville, North Carolina, United States
Rare Diseases
Funding and investments
Nov 18, 2025
7:00 AM EST
Vincere Biosciences Awarded $5 Million from The Michael J. Fox Foundation to Advance Parkinson's Therapeutic Toward Clinical Trials
Cambridge, Massachusetts, United States
Neurology
Phase 2 clinical trials
Nov 18, 2025
6:45 AM EST
Funding and investments
Nov 17, 2025
10:40 PM EST
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
New Haven, Connecticut, United States
Infectious Diseases
Phase 2 clinical trials
Nov 17, 2025
5:30 PM EST
Business deal
Nov 17, 2025
5:23 PM EST
Funding and investments
Nov 17, 2025
4:01 PM EST
Invivyd Announces Proposed Public Offering of Common Stock
New Haven, Connecticut, United States
Infectious Diseases
To see the full list,